Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
Date:3/4/2009

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics -

EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedema (HAE), on Tuesday, March 10, 2009. Lectures will be provided by Anthony J. Castaldo and Janet Long, president and vice president, respectively, of the U.S. Hereditary Angioedema Association (HAEA), and Aleena Banerji, M.D., an HAE specialist at Massachusetts General Hospital.

The 'Teach-in', entitled 'Hereditary Angioedema (HAE) and The Dawn of New Therapeutics' will be held from 5:00 P.M. until 6:30 P.M. Eastern Time on Tuesday March 10, 2009.

"We are thrilled to enlist the participation of these key opinion leaders in the field of hereditary angioedema, who each day deal with the severe ramifications of HAE in their patients, families, and constituents," commented Will Roberts, ViroPharma's vice president of corporate communications. "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to fostering our role as leaders in the space through the execution of essential disease awareness and investor programs."

A live audio webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, http://www.viropharma.com. The archive of the meeting will be available through March 24, 2009.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients wit
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ss., Nov. 27 GSI Group I...r of precision technology products and semiconduct... of the Company,s shareholders has been scheduled ... of the meeting will be announced in due course. ...quisition notice from Stephen Bershad, a holder of...
(Date:11/27/2009)... 27 Considered a highly... years ago, solid organ transplantation is now a l...aordinary men and women who gathered at the Winspe...together from medical centers around the world to ...Transplant Institute (BRTI), one of the pioneers o...
(Date:11/27/2009)...R-SEINE, France, Nov. 27 Team Garm...ling team dedicated to ethical sporting and develo...ounced today that it will become Team Garmin-Trans... a new sponsor of the team. Transitions Optical is...ear, offering the most advanced photochromic techn...
(Date:11/27/2009)... low-emission vehicles may reduce future disease b...27 (HealthDay News) -- Encouraging city dwellers t...er much greater public health benefits than increa...s have found. , The study compared the projecte... transport scenarios for London, England, and Delh...
(Date:11/27/2009)... Voyant Health™ announced today that Spectr...s TraumaCad Enterprise orthopedic templating solut... (PRWEB) November 27, 2009...trum Health (Grand Rapids, Michigan) has licensed ...ution and its TraumaCad Extend workflow solution, ...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...y reserved for patients with Acute Myelogenous Le... transplantation graft failure or engraftme...id formulation; aims to restore US supplies o...on with the United States Food,and Drug Administra...
... faced with even a modest health insurance co-paym...eive these potentially life-saving breast cancer s...rsity and Harvard Medical School researchers. , I...s were 8 percent lower among women with a co-payme...
...,participating vendors raised $137,500 during its ...search and awareness at the Barbara Ann Karmanos,C...cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ...ant cause," said Rick Going, president of The Krog...
...Benefit the National Breast ... response to underbanked,customers, demonstrated d...,Corp., one of the premier providers of prepaid so...cess(R) Visa(R),Prepaid Card to benefit the Nation...
...armaceutical Research & Development, L.L.C. announ...NDA) to the U.S. Food and Drug,Administration (FDA...IR),tablets, an investigational oral analgesic for...ear as a result of injuries or,surgeries, and a re...
...ategies for Aging Baby,Boomers, ALEXANDRIA, Va., ...tion in Florida, the nation,s leading professional...e presidential candidates,of both parties to addre...their families deserve to,know what the next presi...
Other Medicine News:Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 2Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 3Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 4Health News:Health insurance co-payments deter mammography use 2Health News:Health insurance co-payments deter mammography use 3Health News:Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute 2Health News:Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute 3Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 2Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 3Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 4Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Assisted Living Federation Challenges Presidential Candidates 2
(Date:11/24/2009)... 24 /PRNewswire-Asia/ -- Chindex International, In...dent American provider of Western,healthcare produ..., today,announced that the Company will attend the... Conference, to be held December 1 - 2, 2009, at t... currently scheduled to present at 11:30 am ET on ...
(Date:11/24/2009)...ewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: EL...or aortic disorders, announced today that it has f...ngs in, the patent infringement lawsuit brought ag... was filed in the United States District Court in ...ed that the stay remain in effect while the United...
(Date:11/24/2009)...Newswire-FirstCall/ -- Vermillion, Inc. (VRML) (Pi...Plan of Reorganization and Disclosure Statement to...kruptcy Court for the District of Delaware. A hear...nt is presently scheduled for December 8, 2009, wi...eduled for January 7, 2010. ,, The Plan calls ...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo 28R 29 Complete Response Letter 6484 1Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo 28R 29 Complete Response Letter 6484 2News brief 3A Arsenic biomethylation required for oxidative DNA damage 61985 1Children who lack continuity with a regular health care provider miss needed services 61983 1Children who lack continuity with a regular health care provider miss needed services 61983 2Children who lack continuity with a regular health care provider miss needed services 61983 3
....C.--(BUSINESS WIRE)--Apr 25, 2007 - BioDelivery,S...ed today,statistically significant results with BE...gh pain in its pivotal Phase III efficacy,clinical...chievement of the primary efficacy endpoint of the...), compared to placebo., The results demonstrated ...
... 25, 2007 /PRNewswire-USNewswire/ -- At least,one-...r first,appear in childhood or adolescence. Howeve... bipolar symptoms from those of other,disorders, n...th,Letter. , Children, especially young children, ...od episodes of mania and depression.,Also, many sy...
Other Medicine Technology:BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6Bipolar Disorder in Children Difficult to Diagnose, Reports the,Harvard Mental Health Letter 2
Blue Line® Uncuffed Cut-to-Length Oral Endotracheal Tubes (Siliconized) Magill
Blue Line® Cuffed Oral/Nasal Endotracheal Tubes (Ivory) Magill
Uncuffed Oral Preformed
Uncuffed Nasoral Magill
Medicine Products: